224635-57-8

Basic information

• Product Name: 2-Propenoic acid, 3-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-, methyl ester
• CAS NO: 224635-57-8
• Molecular Formula: C15H19NO4
• Molecular Weight: 277.32
• Mol File: 224635-57-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Propenoic acid, 3-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propenoic acid, 3-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-, methyl ester(224635-57-8)
• EPA Substance Registry System: 2-Propenoic acid, 3-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-, methyl ester(224635-57-8)

Safety Data

• Hazardous Substances Data: 224635-57-8(Hazardous Substances Data)

Upstream product

• 292638-85-8 acrylic acid methyl ester 
• 159217-89-7 N-Boc-4-iodoaniline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3236-56-4 dipercarbonate de O,O-t-butyle 
• 139223-62-4 3-(4-aminophenyl)-acrylic acid hydrochloride 
• 74-88-4 methyl iodide 
• 540-37-4 p-aminoiodobenzene 

Downstream Products

• 65198-02-9 3-(4-aminophenyl)-acrylic acid methyl ester 
• 35418-07-6 methyl 3-(4-aminophenyl)propionate 
• 61629-76-3 β-[4-(5-chloro-2-methoxybenzamido)-phenyl]-propionic acid 
• 318510-90-6 methyl 3-(4-((tert-butoxycarbonyl)amino)phenyl)propanoate 

Relevant articles and documents

Preparation of phenylethylbenzamide derivatives as modulators of DNMT3 activity

DNA-methyltransferases (DNMTs) are a class of epigenetic enzymes that catalyze the transfer of a methyl moiety from the methyl donor S-adenosyl-l-methionine onto the C5 position of cytosine in DNA. This process is dysregulated in cancers and leads to the hypermethylation and silencing of tumor suppressor genes. The development of potent and selective inhibitors of DNMTs is of utmost importance for the discovery of new therapies for the treatment of cancer. We report herein the synthesis and DNMT inhibitory activity of 29 analogues derived from NSC 319745. The effect of selected compounds on the methylation level in the MDA-MB-231 human breast cancer cell line was evaluated using a luminometric methylation assay. Molecular docking studies have been conducted to propose a binding mode for this series.

Substituted anilides

The invention is directed to physiologically active compounds of formula (I): wherein: R1is hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy; X1, X2and X6independently represent N or CR10; and one of X3, X4and X5represents CR11and the others independently represents N or CR10; where R10is hydrogen, amino, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, nitro or trifluoromethyl; and R11represents a group —L1—Ar1—L2—Y; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4β1).